Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Inventory (2019 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Change in Inventory for 7 consecutive years, with $72000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory rose 7.46% year-over-year to $72000.0, compared with a TTM value of -$701000.0 through Dec 2025, down 141.33%, and an annual FY2025 reading of -$701000.0, down 141.33% over the prior year.
  • Change in Inventory was $72000.0 for Q4 2025 at Karyopharm Therapeutics, up from -$1.0 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $1.2 million in Q3 2024 and bottomed at -$1.0 million in Q3 2025.
  • Average Change in Inventory over 5 years is $69700.0, with a median of $2500.0 recorded in 2022.
  • The sharpest move saw Change in Inventory surged 743.8% in 2022, then tumbled 185.79% in 2025.
  • Year by year, Change in Inventory stood at $77000.0 in 2021, then crashed by 132.47% to -$25000.0 in 2022, then tumbled by 148.0% to -$62000.0 in 2023, then skyrocketed by 208.06% to $67000.0 in 2024, then increased by 7.46% to $72000.0 in 2025.
  • Business Quant data shows Change in Inventory for KPTI at $72000.0 in Q4 2025, -$1.0 million in Q3 2025, and $223000.0 in Q2 2025.